Cidara Therapeutics, Inc.

0.72 USD
-0.00 (-0.01%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cidara Therapeutics, Inc. stock is up 9.11% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 22.22% of the previous 8 February’s closed higher than January.

About Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc. focuses on the discovery, development, and commercialization of long-acting anti-infectives. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis.